| Today’s Big NewsApr 4, 2024 |
| By Angus Liu Amylyx is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. And 70% of the company's staff will soon lose their jobs. |
|
|
|
By James Waldron Merck KGaA has become the latest biopharma to swell its oncology pipeline with further antibody-drug conjugate potential this week. |
By Conor Hale The multibillion-dollar deal for Axonics and its neurostimulation therapies is now slated to close during the second half of this year. |
By Andrea Park In its first few months of U.S. availability, Pfizer’s Velsipity has already made a splash in the moderate-to-severe ulcerative colitis space, where it’s up against BMS’ Zeposia, a fellow S1P receptor modulator, as well as biologics including AbbVie’s Humira and Rinvoq, J&J’s Stelara, Takeda’s Entyvio and Eli Lilly’s Omvoh. |
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now! 
|
|
By Zoey Becker A Delaware judge sided with Arbutus and Genevant's proposed constructions of the patent claims in question, strengthening their case against Moderna and its COVID-19 vaccine Spikevax. |
By Kevin Dunleavy Sanofi has agreed to settle approximately 4,000 personal injury claims from users of its heartburn drug Zantac, resolving litigation in all U.S. state courts besides Delaware, the company confirmed on Thursday. |
By James Waldron CureVac and GSK have been racing behind Moderna to try and get the first mRNA flu vaccine to market. But now the European partners have come up against the exact same problem as their U.S. competitor when it comes to the "historically challenging" B strains of influenza. |
By Kevin Dunleavy Fifteen years after Basilea's antibiotic ceftobiprole sustained a rejection from the FDA, the company has finally won over the U.S. regulator and done so in triplicate. The FDA has approved Basilea’s Zevtera for three different kinds of infections. |
By Conor Hale In a world first, a man with end-stage renal disease is now enjoying "one of the cleanest bills of health" in a long time, following a xenotransplant procedure at Massachusetts General Hospital. |
By Fraiser Kansteiner Teva has unveiled a fresh in-licensing accord with Spain’s mAbxience to chip in on an investigational biosimilar spanning multiple oncology indications. Under the deal, Teva will oversee regulatory duties and marketing for the biosimilar, while mAbxience is on the hook to continue developing and manufacturing the drug at its production sites in Spain and Argentina. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. |
|
|---|
|
|
|
Available On-Demand Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Access this discussion on-demand to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. View now. 
|
|
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
